Nektar Therapeutics

BMV:NKTR * Stock Report

Market Cap: Mex$2.5b

Nektar Therapeutics Management

Management criteria checks 2/4

Nektar Therapeutics' CEO is Howard Robin, appointed in Jan 2007, has a tenure of 18.33 years. total yearly compensation is $3.76M, comprised of 28.8% salary and 71.2% bonuses, including company stock and options. directly owns 0.52% of the company’s shares, worth MX$13.00M. The average tenure of the management team and the board of directors is 4.5 years and 16.8 years respectively.

Key information

Howard Robin

Chief executive officer

US$3.8m

Total compensation

CEO salary percentage28.82%
CEO tenure18.3yrs
CEO ownership0.5%
Management average tenure4.5yrs
Board average tenure16.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Howard Robin's remuneration changed compared to Nektar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$133m

Dec 31 2024US$4mUS$1m

-US$119m

Sep 30 2024n/an/a

-US$168m

Jun 30 2024n/an/a

-US$177m

Mar 31 2024n/an/a

-US$176m

Dec 31 2023US$3mUS$1m

-US$276m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$307m

Mar 31 2023n/an/a

-US$415m

Dec 31 2022US$11mUS$1m

-US$368m

Sep 30 2022n/an/a

-US$454m

Jun 30 2022n/an/a

-US$525m

Mar 31 2022n/an/a

-US$491m

Dec 31 2021US$11mUS$1m

-US$524m

Sep 30 2021n/an/a

-US$495m

Jun 30 2021n/an/a

-US$474m

Mar 31 2021n/an/a

-US$429m

Dec 31 2020US$11mUS$1m

-US$444m

Sep 30 2020n/an/a

-US$439m

Jun 30 2020n/an/a

-US$429m

Mar 31 2020n/an/a

-US$460m

Dec 31 2019US$10mUS$1m

-US$441m

Sep 30 2019n/an/a

-US$427m

Jun 30 2019n/an/a

-US$424m

Mar 31 2019n/an/a

US$657m

Dec 31 2018US$13mUS$969k

US$681m

Compensation vs Market: Howard's total compensation ($USD3.76M) is above average for companies of similar size in the MX market ($USD185.89K).

Compensation vs Earnings: Howard's compensation has increased whilst the company is unprofitable.

CEO

Howard Robin (71 yo)

18.3yrs

Tenure

US$3,762,693

Compensation

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...

Leadership Team

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director18.3yrsUS$3.76m0.52%
MX$ 13.0m
Sandra Gardiner
CFO and Principal Financial & Accounting Officer2.1yrsUS$460.85kno data
Mark Wilson
Senior VP8.8yrsUS$1.30m0.15%
MX$ 3.7m
Jonathan Zalevsky
Senior VP and Chief Research & Development Officer5.6yrsUS$1.61m0.15%
MX$ 3.8m
Jason Barnard
Chief Accounting Officerless than a yearno datano data
Robert Bacci
Chief People Officer and Head of Quality & Facilities3.4yrsno datano data
Jennifer Ruddock
Chief Business Officer6.3yrsno datano data
Brian Kotzin
Interim Chief Medical Officerless than a yearno datano data

4.5yrs

Average Tenure

58yo

Average Age

Experienced Management: NKTR *'s management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director18.3yrsUS$3.76m0.52%
MX$ 13.0m
Robert Chess
Independent Chairman of the Board33yrsUS$239.44k0.14%
MX$ 3.4m
R. Greer
Independent Director15.3yrsUS$223.94k0.16%
MX$ 4.0m
Roy Whitfield
Lead Independent Director24.8yrsUS$230.94k0.15%
MX$ 3.8m
Jeffrey Ajer
Independent Director7.7yrsUS$197.94k0.018%
MX$ 455.6k
Diana Brainard
Independent Director3.5yrsUS$197.94k0.015%
MX$ 381.1k

16.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: NKTR *'s board of directors are seasoned and experienced ( 16.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 01:23
End of Day Share Price 2025/02/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nektar Therapeutics is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Aydin HuseynovBenchmark Company
George FarmerBMO Capital Markets Equity Research